Sarah H. Millan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sarah H. Millan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Amanda D. Currie
Department of Neurology, Vanderbilt University Medical Center, 1611 21st Ave S., A-0118 Medical Center North, Nashville, TN 37223-2551, USA
1 shared publicationAnn Hu
Georgetown University School of Medicine Washington DC USA
1 shared publicationAnna L. Molinari
Department of Neurology, Vanderbilt University Medical Center, 1611 21st Ave S., A-0118 Medical Center North, Nashville, TN 37223-2551, USA
1 shared publication- Ben W. Gratz
Georgetown University School of Medicine, Washington, DC, USA
1 shared publication Claudia Fernandez Perez
Georgetown University School of Medicine Washington DC USA
1 shared publicationHolly D. Shan
Georgetown University School of Medicine Washington DC USA
1 shared publication
Latest Publications
- Open Access
- 18 September 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (1) , 3-10
Treatment Strategies for Pediatric Trichotillomania: State‐of‐the‐Art Review on Progress and Persistent Challenges
Trichotillomania (TTM) is a condition characterized by recurrent hair pulling, often resulting in hair loss and functional impairment. The disorder remains underreported in the pediatric population, despite high rates of psychiatric comorbidities. Moreover, diagnosing and treating TTM among children remains challenging due to a lack of standardized guidelines. Hence, this systematic review aims to evaluate the current treatment approaches for pediatric TTM. A comprehensive search was conducted of five databases, using the search concepts of trichotillomania, pediatric populations, and treatments/interventions. Studies were included if they (1) directly addressed the topic, (2) were of an appropriate study type (e.g., clinical trials, case–control studies, cohort studies, cross‐sectional studies, or interview studies), (3) were published within the past 10 years, and (4) appeared in peer‐reviewed journals published in English. Ultimately, 10 studies met our inclusion criteria, from which data were extracted and synthesized following formal quality assessment. Our results indicate that behavioral interventions, particularly habit reversal training, consistently demonstrated the greatest therapeutic benefit. Pharmacological treatments, including selective serotonin reuptake inhibitors, have been explored in various case series. Although some individuals have shown improvement, overall evidence remains insufficient to support pharmacotherapy as first‐line. Alternative therapies, such as N‐acetylcysteine, have also been studied, though findings are variable and require further investigation in pediatric cohorts. Our review underscores the importance of early behavioral intervention and the need for larger, controlled studies to inform standardized treatment protocols. Given the functional and psychosocial burden of TTM in youth, comprehensive management strategies are essential.
- 18 September 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (1) , 3-10
Open AccessTreatment Strategies for Pediatric Trichotillomania: State‐of‐the‐Art Review on Progress and Persistent Challenges
Trichotillomania (TTM) is a condition characterized by recurrent hair pulling, often resulting in hair loss and functional impairment. The disorder remains underreported in the pediatric population, despite high rates of psychiatric comorbidities. Moreover, diagnosing and treating TTM among children remains challenging due to a lack of standardized guidelines. Hence, this systematic review aims to evaluate the current treatment approaches for pediatric TTM. A comprehensive search was conducted of five databases, using the search concepts of trichotillomania, pediatric populations, and treatments/interventions. Studies were included if they (1) directly addressed the topic, (2) were of an appropriate study type (e.g., clinical trials, case–control studies, cohort studies, cross‐sectional studies, or interview studies), (3) were published within the past 10 years, and (4) appeared in peer‐reviewed journals published in English. Ultimately, 10 studies met our inclusion criteria, from which data were extracted and synthesized following formal quality assessment. Our results indicate that behavioral interventions, particularly habit reversal training, consistently demonstrated the greatest therapeutic benefit. Pharmacological treatments, including selective serotonin reuptake inhibitors, have been explored in various case series. Although some individuals have shown improvement, overall evidence remains insufficient to support pharmacotherapy as first‐line. Alternative therapies, such as N‐acetylcysteine, have also been studied, though findings are variable and require further investigation in pediatric cohorts. Our review underscores the importance of early behavioral intervention and the need for larger, controlled studies to inform standardized treatment protocols. Given the functional and psychosocial burden of TTM in youth, comprehensive management strategies are essential.
- 22 April 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (9) , 1762-1764
Chronic Venous Insufficiency Associated With Nonconscious Proprioception Irregularities
- 22 April 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (9) , 1762-1764
Chronic Venous Insufficiency Associated With Nonconscious Proprioception Irregularities
- Open Access
- 1 January 2017
- Published by Wiley in Parkinson's Disease
- Vol. 2017, 1-4
Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Is Not Associated with Increased Body Mass Index
Previous studies suggest that deep brain stimulation of the subthalamic nucleus (STN-DBS) for Parkinson’s disease (PD) leads to weight gain. This study analyzes changes in body mass index (BMI) in 29 subjects from a prospective, single-blind trial of DBS in early stage PD (age 50–75, Hoehn & Yahr stage II off medication, treated with antiparkinsonian medications for ≥6 months but <4 years, and without a history of motor fluctuations, dyskinesias, or dementia). Subjects were randomized to DBS plus optimal drug therapy (DBS+ODT;) or ODT () and followed for 24 months. Weight and height were recorded at baseline and each follow-up visit and used to calculate BMI. BMIs were compared within and between groups using nonparametric-tests. Mean BMI at baseline was 29.7 in the ODT group and 32.3 in the DBS+ODT group (). BMI change over two years was not different between the groups (, ODT = −0.89; DBS+ODT = −0.17). This study suggests that STN-DBS is not associated with weight gain in subjects with early stage PD. This finding will be tested in an upcoming FDA-approved phase III multicenter, randomized, double-blind, placebo-controlled, pivotal clinical trial evaluating DBS in early stage PD (ClinicalTrials.gov identifierNCT00282152).- 1 January 2017
- Published by Wiley in Parkinson's Disease
- Vol. 2017, 1-4
Open AccessSubthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Is Not Associated with Increased Body Mass Index
Previous studies suggest that deep brain stimulation of the subthalamic nucleus (STN-DBS) for Parkinson’s disease (PD) leads to weight gain. This study analyzes changes in body mass index (BMI) in 29 subjects from a prospective, single-blind trial of DBS in early stage PD (age 50–75, Hoehn & Yahr stage II off medication, treated with antiparkinsonian medications for ≥6 months but <4 years, and without a history of motor fluctuations, dyskinesias, or dementia). Subjects were randomized to DBS plus optimal drug therapy (DBS+ODT;) or ODT () and followed for 24 months. Weight and height were recorded at baseline and each follow-up visit and used to calculate BMI. BMIs were compared within and between groups using nonparametric-tests. Mean BMI at baseline was 29.7 in the ODT group and 32.3 in the DBS+ODT group (). BMI change over two years was not different between the groups (, ODT = −0.89; DBS+ODT = −0.17). This study suggests that STN-DBS is not associated with weight gain in subjects with early stage PD. This finding will be tested in an upcoming FDA-approved phase III multicenter, randomized, double-blind, placebo-controlled, pivotal clinical trial evaluating DBS in early stage PD (ClinicalTrials.gov identifierNCT00282152).